Protara Therapeutics
TARA
114 hedge funds and large institutions have $237M invested in Protara Therapeutics in 2026 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 23 reducing their positions, and 21 closing their positions.
435% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $245K
109% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 23
48% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 21
12% more capital invested
Capital invested by funds: $212M → $237M (+$25.1M)
9% more funds holding
Funds holding: 105 → 114 (+9)
7.1% more ownership
Funds ownership: 77.14% → 84.24% (+7.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$12.3M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$9.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.66M |
| 4 |
PSC
Patient Square Capital
Menlo Park,
California
|
+$6.1M |
| 5 |
BlackRock
New York
|
+$5.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$6.71M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.56M |
| 3 |
CCM
Catalio Capital Management
New York
|
-$5.13M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$4.02M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.46M |
TARA Hedge Fund Activity: Q1 2026 in Review
114 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2026, worth a combined $237M — up 12% from $212M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TARA positions and 21 closed out — a net gain of 10 holders — while 48 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, adding an estimated $12.3M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $6.71M sold.
- 114 institutional investors held Protara Therapeutics (TARA) as of Q1 2026, up from 105 in Q4 2025.
- Funds reported $237M of Protara Therapeutics stock for Q1 2026, up 12% quarter-over-quarter.
- 31 funds opened new Protara Therapeutics positions in Q1 2026 and 21 closed out, a net change of +10 holders.
- The largest Protara Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $12.3M added.
- The largest Protara Therapeutics seller in Q1 2026 was Driehaus Capital Management, an estimated $6.71M sold.
Based on aggregated 13F filings for Q1 2026.